Division of Miraca Holdings Inc.
Latest From Fujirebio Inc.
Not all initial public offerings are taken up, even in the best of funding years. Of the 54 life sciences IPOs registered in 1997, 11 (20%) were withdrawn because of pricing issues or lack of interest.
The Japanese firm Fujirebio is to pay ¥9.8 billion ($112.9 million) for Innogenetics, a Belgian diagnostics and biologics operation acquired by Abbott as part of the US firm's broader purchase of Solvay Pharmaceuticals earlier this year.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Therapeutic Areas
- Infectious & Viral Diseases
- Pacific Rim
- Parent & Subsidiaries
- Miraca Holdings Inc.
- Senior Management
- Yoshihiro Ashihara, Pres. & CEO
- Contact Info
Phone: (81) 3-6279-0800
2-1-1 Nishishinjuku, Shinjuku-ku
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.